Research location
Launceston
Australia
Advertisement
Research activity in Launceston
AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Launceston
8 linked trials · page 1 of 1A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT02125461 · 2014-05-07 · 1 site observation
COMPLETED
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsNCT02111564 · 2014-01-07 · 1 site observation
COMPLETED
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureNCT01877915 · 2013-09-10 · 1 site observation
COMPLETED
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsNCT01107886 · 2010-05-01 · 1 site observation
COMPLETED
CANVAS - CANagliflozin cardioVascular Assessment StudyNCT01032629 · 2009-12-09 · 1 site observation
COMPLETED
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailureNCT00475852 · 2007-05-01 · 1 site observation
COMPLETED
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesNCT01467375 · 2001-01-08 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.